Tirzepatide as a novel therapeutic option for patients with type 2 diabetes: A pooled analysis of subgroups of SURPASS 1-5 trials
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Aim: The aim of this study was to evaluate the impact of patients’ characteristics on the efficacy and the safety of subcutaneous tirzepatide once-weekly in patients with uncontrolled type 2 diabetes mellitus (T2DM). Materials and Methods: This post hoc analysis of pooled SURPASS 1-5 randomized controlled trials narratively examined changes from baseline in hemoglobin A1c (HbA1c) and body weight and the proportions of patients who achieved the endpoint composite HbA1c with tirzepatide (5, 10, and 15 mg) across the following subgroups; baseline HbA1c (≥ 7.5% to ≤8.0% [≥48 ≤ 64 mmol/mol], ≥8.0% to ≤8.5% [≥64 ≤68 mmol/mol], and ≥ 8.5% to ≤9.0% [≥68 ≤75 mmol/mol]), baseline diabetes durations (≤ 5 years, 5–10 years, and ≥ 10 years), and age (non-elderly ≤ 60 years and elderly ≥ 60 years). Results: Based on diabetes duration, the mean HbA1c reduced from baseline (≥–1.87 % to ≤–2.24% [≥–20.57 to ≤–24.64 mmol/mol]) for tirzepatide 5 mg ( P = 0.308), –1.89 % to –2.43% (–20.79 to –26.73 mmol/mol) with tirzepatide 10 mg ( P = 0.015) and ≥–2.07 % to≤ –2.58 % (≥–22.77 to ≤–28.38 mmol/mol) with tirzepatide 15 mg ( P = 0.010). Similar HbA1c and body weight reductions were observed across other subgroups (baseline HbA1c and age). Conclusion: Tirzepatide was consistently efficacious and safe in the broad spectrum of patients with T2DM subgroups across the SURPASS 1-5 trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pooled post-hoc analyses of SURPASS 1–5 (NCT03954834, NCT03987919, NCT03882970, NCT03730662, and NCT04039503) showed that weight loss was similar in participants aged ≥ 60 and < 60 years [64]”
From GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity (2026) · doi:10.1007/s13668-026-00777-x · cites this paper as [64]
Citations
Cites
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Ahlqvist, E., Storm, P., Käräjämäki, A., Martinell, M., Dorkhan, M., Carlsson, A., Vikman, P., Prasad, R. B., Aly, D. M., Almgren, P., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30051-2 · Cited by 2,335
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080
Del Prato, S., Kahn, S. E., Pavo, I., Weerakkody, G. J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A. G., Riesmeyer, J. S., Heine, R. J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02188-7 · Cited by 684
Ludvik, B., Giorgino, F., Jódar, E., Frias, J. P., Fernández Landó, L., Brown, K., Bray, R., & Rodríguez, Á. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01443-4 · Cited by 639
Dahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., & Rodríguez, Á. (2022) · JAMA · doi:10.1001/jama.2022.0078 · Cited by 597
Pratley, R., Amod, A., Hoff, S. T., Kadowaki, T., Lingvay, I., Nauck, M., Pedersen, K. B., Saugstrup, T., & Meier, J. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31271-1 · Cited by 594
Cited by
Pharmacological Treatment of Obesity in Older Adults
Žižka, O., Haluzík, M., & Jude, E. B. (2024) · Drugs & Aging · doi:10.1007/s40266-024-01150-9 · Cited by 23
“The baseline age for all tirzepatide doses had no significant effect on body weight reduction effect (for tirzepatide 5 mg: p = 0.198, tirzepatide 10 mg: p = 0.600 and tirzepatide 15 mg: p = 0.608) [70].”
BackgroundInfluentialMedicare Part D Coverage of Anti-obesity Medications: a Call for Forward-Looking Policy Reform
Hernandez, I., Wright, D. R., Guo, J., & Shrank, W. H. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-023-08416-9 · Cited by 18
Antiobesity Medications for Older Adults—the New, the Good, the Bad, and the Unknown
Pendrey, A., & Sevilla‐Martir, J. (2025) · Obesity · doi:10.1002/oby.70029 · Cited by 11
“Tirzepatide was safe and efficacious in all the subgroups in these trials [53].”
Influential(2026) · doi:10.1007/s13668-026-00777-x · Cited by 10
“…of SURPASS 1–5 (NCT03954834, NCT03987919, NCT03882970, NCT03730662, and NCT04039503) showed that weight loss was similar in participants aged ≥ 60 and < 60 years [64]; however, this population was not evaluated in terms of detailed body composition, which is particularly relevant in older adults.”
Dsouza, P. D., Chitralu, S. P. P., Khan, R., & Nyamagoud, S. B. (2025) · MGM Journal of Medical Sciences · doi:10.4103/mgmj.mgmj_386_24 · Cited by 3
Metadata
- Authors
- Abdalla, M. A., Soyiri, I., Atkin, S., & Sathyapalan, T.
- Affiliations
- University of Hull (GB)
- Royal College of Surgeons in Ireland - Bahrain (BH)
- Corresponding author
- Abdalla, Mohammed Altigani
- Venue
- Journal of Diabetology
- Published
- 2023-04
- Volume
- 14
- Issue
- 2
- Pages
- 65-73
- ISSN
- 2078-7685 (ISSN-L)
- 2543-3288
- OpenAlex
- W4378908091
- Cited by
- 8
- References
- 21
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 1 · 2023: 1
- FWCI
- 1.64
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc-sa
- Locations
- Journal of Diabetology (publishedVersion, cc-by-nc-sa)
- Repository@Hull (Worktribe) (University of Hull) (publishedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- tirzepatide, type 2 diabetes, SURPASS trials, glycemic control, HbA1c reduction, weight loss, diabetes duration, baseline HbA1c, elderly patients, subgroup analysis, drug safety and efficacy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tirzepatide as a novel therapeutic option for patients with type 2 diabetes: A pooled analysis of subgroups of SURPASS 1-5 trials. https://app.cochat.ai/papers/10.4103/jod.jod_16_23
- The paper
- Abdalla, M. A., Soyiri, I., Atkin, S., & Sathyapalan, T. (2023). Tirzepatide as a novel therapeutic option for patients with type 2 diabetes: A pooled analysis of subgroups of SURPASS 1-5 trials. Journal of Diabetology. https://doi.org/10.4103/jod.jod_16_23
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.